beta-lactams has been researched along with Diabetic Feet in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carvalho, VC; Lima, AL; Oliveira, PR; Peixoto de Miranda, EJ | 1 |
| Kumar, A; Shahi, SK; Singh, VK | 1 |
| Castaing, N; Cooper, A; Dartois, N; Dukart, G; Embil, JM; Lauf, L; Maroko, R; Mitha, I; Ozsvár, Z; Regöly-Mérei, J; Sabol, MB; Yan, J | 1 |
| Munckhof, WJ; Oo, Y; Packham, D; Yau, W | 1 |
| Gan, WJ; Mu, SM; Ran, XW; Shen, JF; Wang, J; Xian, Y; Xu, ZR; Yan, XD; Yuan, GY; Zhang, BS | 1 |
| Cavaco-Silva, P; Matias, CS; Melo-Cristino, J; Mendes, JJ; Mottola, C; Oliveira, M; Tavares, L | 1 |
| Carmeli, Y; Jansen, JP; Kumar, R | 1 |
| Edmonds, M | 1 |
| Khan, AU; Nordmann, P | 1 |
| Ahmad, J; Malik, A; Zubair, M | 1 |
| Burian, A; Burian, B; Höferl, M; Jäger, W; Riedl, M; Sauermann, R; Stella, A; Theurer, S; Zeitlinger, M | 1 |
| Abramson, MA; Armstrong, DG; Citron, DM; Lipsky, BA; Morgenstern, DE; Tice, AD | 1 |
| Armstrong, DG; Bevilacqua, NJ; Rogers, LC | 1 |
| Abramson, MA; Armstrong, DG; Lipsky, BA; Polis, AB; Sheehan, P; Tice, AD | 1 |
| Abramson, MA; Hoey, CT; Lipsky, BA; Tice, AD; Turpin, RS; Wu, J | 1 |
| Bouziges, N; Jourdan, N; Lavigne, JP; Lemaire, X; Richard, JL; Sotto, A | 1 |
| Akalin, HE | 1 |
5 review(s) available for beta-lactams and Diabetic Feet
| Article | Year |
|---|---|
[Microbiology of diabetic foot infections: role of ertapenem].
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Drug Resistance, Bacterial; Ertapenem; Humans; Microbial Sensitivity Tests | 2013 |
Ertapenem-associated psychosis and encephalopathy.
Topics: Anti-Bacterial Agents; beta-Lactams; Diabetic Foot; Ertapenem; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Psychoses, Substance-Induced; Severity of Illness Index; Wound Infection | 2014 |
The treatment of diabetic foot infections: focus on ertapenem.
Topics: Administration, Oral; Anti-Bacterial Agents; beta-Lactams; Combined Modality Therapy; Debridement; Diabetic Foot; Drug Administration Schedule; Ertapenem; Humans; Infusions, Intravenous; Osteomyelitis; Severity of Illness Index; Treatment Outcome; Vascular Surgical Procedures | 2009 |
Ertapenem for diabetic foot infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Diabetic Foot; Ertapenem; Humans | 2006 |
The role of beta-lactam/beta-lactamase inhibitors in the management of mixed infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Brain Abscess; Diabetic Foot; Drug Therapy, Combination; Endometritis; Enzyme Inhibitors; Female; Humans; Peritonitis; Surgical Wound Infection | 1999 |
3 trial(s) available for beta-lactams and Diabetic Feet
| Article | Year |
|---|---|
Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Diabetic Foot; Drug-Related Side Effects and Adverse Reactions; Ertapenem; Female; Humans; Male; Middle Aged; Minocycline; Nausea; Osteomyelitis; Tigecycline; Treatment Outcome; Vancomycin; Vomiting; Young Adult | 2014 |
Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactams; China; Diabetic Foot; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Ertapenem; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome; Young Adult | 2016 |
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Diabetic Foot; Double-Blind Method; Drug Administration Schedule; Ertapenem; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Severity of Illness Index; Treatment Outcome | 2005 |
9 other study(ies) available for beta-lactams and Diabetic Feet
| Article | Year |
|---|---|
Detection of Escherichia coli and associated β-lactamases genes from diabetic foot ulcers by multiplex PCR and molecular modeling and docking of SHV-1, TEM-1, and OXA-1 β-lactamases with clindamycin and piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clindamycin; Diabetic Foot; Escherichia coli; Escherichia coli Infections; Gene Expression; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Multiplex Polymerase Chain Reaction; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Structural Homology, Protein; Structure-Activity Relationship | 2013 |
Susceptibility patterns of Staphylococcus aureus biofilms in diabetic foot infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Biofilms; Ceftaroline; Cephalosporins; Diabetic Foot; Gentamicins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Polymerase Chain Reaction; Staphylococcal Infections; Staphylococcus aureus | 2016 |
Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cost-Benefit Analysis; Decision Trees; Diabetic Foot; Direct Service Costs; Drug Costs; Drug Resistance, Bacterial; Ertapenem; Humans; Models, Biological; Models, Econometric; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Treatment Outcome; United Kingdom | 2009 |
NDM-1-producing Enterobacter cloacae and Klebsiella pneumoniae from diabetic foot ulcers in India.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Diabetic Foot; DNA, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Genes, Bacterial; Humans; India; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Skin Diseases, Bacterial; Ulcer | 2012 |
Study of plasmid-mediated extended-spectrum β-lactamase-producing strains of enterobacteriaceae, isolated from diabetic foot infections in a North Indian tertiary-care hospital.
Topics: Amputation, Surgical; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Diabetic Foot; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Gangrene; Genotype; Humans; India; Male; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Risk Factors | 2012 |
Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Ertapenem; Female; Humans; Male; Middle Aged; Plasma; Skin; Young Adult | 2013 |
Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Ertapenem; Female; Humans; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Treatment Failure | 2007 |
Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Drug Administration Schedule; Drug Combinations; Ertapenem; Female; Health Care Costs; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
[In vitro activity of ertapenem against strains isolated from diabetic foot infections].
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Diabetic Foot; Drug Evaluation, Preclinical; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Inpatients; Microbial Sensitivity Tests; Species Specificity; Staphylococcal Infections | 2008 |